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T he ACCORD BP study (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) demonstrated that compared with the standard systolic BP target of <140 mm Hg, the intensive systolic BP target of <120 mm Hg in high-risk patients with type 2 diabetes mellitus showed no reduction in the composite outcome of fatal and nonfatal major cardiovascular events. 1 The different results between the ACCORD BP and other studies might be attributed to not only different subjects and BP measurements but also different composite outcomes of cardiovascular events. 1, 2 The cardiovascular events of the ACCORD BP study did not include heart failure. In addition, because participants in the ACCORD BP study were patients with diabetes mellitus, hypoglycemic events might have led to the different results. The aim of the present study was to assess whether the intensive BP treatment, compared with the standard BP treatment, has benefits in preventing cardiovascular events, including heart failure, in patients receiving either standard or intensive glycemic control.
Methods
The anonymized ACCORD data have been made publicly available at the National Heart, Lung, and Blood Institute and can be accessed at https://biolincc.nhlbi.nih.gov/studies/accord/.
Study Design
Using data from the ACCORD BP trial, 1, 3 we assessed the effects of intensive BP treatment in patients receiving standard or intensive glycemic control. The detailed protocol, study design, and patients' characteristics of the ACCORD trial have been previously reported. [3] [4] [5] [6] In brief, the ACCORD trial was sponsored by the National Heart, Lung, and Blood Institute and was conducted in 77 clinical centers across the United States and Canada. 3 A total of 10 251 patients with type 2 diabetes mellitus and a glycohemoglobin level of ≥7.5% were included. The patients were either between the ages of 40 and 79 years and had cardiovascular disease or between the ages of 55 and 79 years and had anatomic evidence of significant atherosclerosis, left ventricular hypertrophy, albuminuria, or at least 2 additional cardiovascular disease risk factors (obesity, current smoker, dyslipidemia, or hypertension). 1, 3, 4 Exclusion criteria included nonconsent to receive home glucose monitoring or insulin injection, body mass index (weight in kilogram divided by the square height in meters) of >45, frequent or recent serious hypoglycemia, serum creatinine level of >1.5 mg/dL, or any other serious illness. All 10 251 patients were randomly assigned to the standard glycemic control that targeted a level of 7.0%-7.9% or the intensive glycemic control that targeted a glycohemoglobin level of <6.0%. 3 In addition, the ACCORD participants were also randomly assigned to either the ACCORD BP trial or the ACCORD lipid trial (a 2-by-2 factorial design). 1, 3 The participants of the ACCORD BP trial were randomly assigned to standard BP treatment that targeted systolic BPs of <140 mm Hg or intensive BP treatment that targeted systolic BPs of <120 mm Hg. 1 The ACCORD BP participants were followed up at least every 4 months to monitor study outcomes and to ensure that therapeutic goals were met and maintained. 3 Occurrence of outcomes in the present study was maximally followed up for 6 years. The institutional review board of the National Center for Global Health and Medicine approved the present study. The National Heart, Lung, and Blood Institute approved the use of ACCORD data.
Outcome Measurements
The primary outcome in the present study was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalized congestive heart failure. Secondary outcomes were all-cause death, major coronary events (fatal coronary heart disease, nonfatal myocardial infarction, or unstable angina), stroke (fatal or nonfatal stroke), and heart failure (fatal or hospitalized congestive heart failure). Cardiovascular death was defined as unexpected death, presumed cardiovascular death, and death from myocardial infarction, congestive heart failure, arrhythmia, stroke, and other cardiovascular diseases, including pulmonary emboli and abdominal aortic aneurysm rupture. 4 The cardiovascular events were classified by a Working Group of the Morbidity and Mortality subcommittee. Each outcome event, including congestive heart failure, was prespecified. Hospitalized congestive heart failure was confirmed with documented clinical or radiological evidence.
Statistical Analysis
Patients in the present study were first divided into 2 groups according to the glycemic control strategies (standard or intensive glycemic control). Demographic data are presented as proportions or means±SDs. Categorical variables were compared using χ 2 tests, and continuous variables were compared using t tests. Kaplan-Meier survival curves were constructed and event rates of primary and secondary outcomes were calculated in patients receiving standard or intensive BP treatment. Applying the randomized design of the ACCORD BP trial, hazard ratios (HRs) for primary and secondary outcomes with 95% confidence intervals (CIs) were calculated. We used the Cox proportional hazard models to compare the time to the first occurrence of a primary or secondary outcome event in the standard and intensive BP treatments individually in patients receiving either standard or intensive glycemic control. A subanalysis of primary outcome was performed in patients with hypertension at baseline. Because the number of events within 1 year was small and there were concerns on the subject identification, the follow-up times for primary and secondary outcome events within 1 year were combined by the National Heart, Lung, and Blood Institute before our data analyses. We assumed that the events within 1 year occurred at 6 months. We performed several sensitivity analyses to exclude the potential effects of combined events within 1 year. We compared the incidence of primary-outcome events within 1 year by intensive BP treatment with standard BP treatment in each patient receiving standard and intensive glycemic control. In addition, we conducted further analyses using Cox proportional hazard models using data from 1 year after the follow-up.
The association between the intensive BP treatment and the primary outcome in patients receiving standard glycemic control was further analyzed according to the following subgroups: age (<65 or ≥65 years), sex (male or female), obesity (nonobese or obese), duration of diabetes mellitus (<10 or ≥10 years), cardiovascular disease (no history or prior history of cardiovascular disease), use of insulin (noninsulin user or insulin user), glycohemoglobin (<8% or ≥8%), and systolic BP (<140 or ≥140 mm Hg). We tested for interactions between BP treatment strategy and these subgroups to investigate the effects of treatment modification.
All statistical analyses were conducted using the Stata software (version 14.1; Stata Corp, College Station, TX). A P value of <0.05 was considered statistically significant for all tests.
Results

Patient Characteristics and BP During Follow-Up
The present study included 4733 patients with type 2 diabetes mellitus: 2362 patients receiving standard glycemic control and 2371 patients receiving intensive glycemic control. The characteristics of patients in the standard and intensive BP treatment groups are presented in Table 1 . The baseline characteristics of patients did not differ significantly between the standard and intensive BP treatment groups in both patients receiving standard and intensive glycemic controls. BP levels rapidly decreased with intensive BP treatment and were significantly lower during follow-up in the intensive BP treatment group than in the standard BP treatment group ( Figure S1 in the online-only Data Supplement). The mean (SD) systolic BP levels in the standard and intensive BP treatment groups were 134.9 (13.6) versus 120.6 (13.4) 
Primary and Secondary Outcomes
The overall mean (SD) follow-up period was 4.5 (1.4) years, and a primary-outcome event was confirmed in 528 patients. Kaplan-Meier survival curves and cumulative event rates for primary and secondary outcomes in the standard and intensive BP treatment groups are shown in Figure 1 and Table 2 , respectively. In patients receiving standard glycemic control, the primary-outcome event rates were 29.7/1000 person-years in the standard BP treatment group and 21.1/1000 person-years in the intensive BP treatment group; we found the risk of a primary-outcome event to be significantly lower in the intensive BP treatment group than in the standard BP treatment group (HR, 0.71; 95% CI, 0.56-0.90; P=0.005). In patients receiving intensive glycemic control, primary-outcome event rates were 23.2/1000 person-years in the standard BP treatment group and 24.9/1000 person-years in the intensive BP treatment group; the primary-outcome event risks did not differ significantly between the groups (HR, 1.06; 95% CI, 0.83-1.36; P=0.61). There was significant interaction between BP treatment strategy and glycemic control (P for interaction=0.02). Similar results were observed limited to patients with hypertension (standard glycemic control: HR, 0.69; 95% CI, 0.54-0.87; P=0.002; Data are presented as number of participants, percent, or mean (SD). P value was calculated by comparing variables in intensive BP treatment with those in standard BP treatment. Standard BP denotes standard BP treatment, and intensive BP denotes intensive BP treatment. HbA1c: 8.3%=67 mmoL/moL. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; BP, blood pressure; CCB, calcium channel blockers; eGFR, estimated glomerular filtration rate. *Body mass index was calculated as weight in kilogram divided by the square of height in meters. †Obesity was defined as body mass index ≥30 kg/m 2 . ‡Cardiovascular disease was defined as coronary heart disease or stroke. Coronary heart disease was defined as myocardial infarction or angina pectoris. §The estimated GFR was calculated using the following MDRD study ( intensive glycemic control: HR, 1.07; 95% CI, 0.84-1.37; P=0.59). The incidence of a primary-outcome event within 1 year in patients receiving standard glycemic control was significantly lower in the intensive BP treatment group than in the standard BP treatment group (1.5% versus 3.0%; P=0.01), whereas that in patients receiving intensive glycemic control was significantly higher in the intensive BP treatment group (3.2% versus 1.8%; P=0.03). Kaplan-Meier survival curves for the following periods are shown in Figure S2 . Analyses did not change the overall results (standard glycemic control: HR, 0.76; 95% CI, 0.58-0.98; P=0.03 and intensive glycemic control: HR, 0.92; 95% CI, 0.70-1.22; P=0.56). Figure 2 shows the Kaplan-Meier survival curves for secondary outcomes in the standard and intensive BP treatment groups in patients receiving standard glycemic control. The risk of stroke in patients receiving standard glycemic control was significantly lower in the intensive BP treatment group than in the standard BP treatment group (HR, 0.49; 95% CI, 0.27-0.87; P=0.01). The risk of all-cause and cardiovascular death, major coronary events, and heart failure in patients receiving standard glycemic control was lower in the intensive BP treatment group than in the standard BP treatment group, although there was no significant difference between the 2 groups. In patients receiving intensive glycemic control, the risk of stroke was not significantly different between the standard and intensive BP treatment groups (HR, 0.77; 95% CI, 0.42-1.43; P=0.41). The risk of other outcomes also did not significantly differ between the 2 BP treatment groups ( Figure S3 ). All-cause mortality in patients receiving intensive glycemic control was nonsignificantly higher in patients receiving intensive BP treatment than in those receiving standard BP treatment (HR, 1.38; 95% CI, 0.99-1.92; P=0.05). In regard to all-cause mortality, there was a significant interaction between BP treatment strategy and glycemic control (P for interaction=0.03). Figure 3 shows the association between BP treatment strategy and primary outcome in different subgroups with standard glycemic control. There were no significant interactions between the BP treatment strategy and age, sex, obesity, duration of diabetes mellitus, history of cardiovascular disease, use of insulin, glycohemoglobin levels, or systolic BP levels.
Discussion
The present study demonstrated that the intensive BP treatment in patients receiving standard glycemic control resulted in a decreased risk of cardiovascular events including heart failure in patients with high-risk type 2 diabetes mellitus. Meanwhile, in patients receiving intensive glycemic control, the risk of cardiovascular events was not significantly different between the standard and intensive BP treatment groups. In addition, the risk of stroke in patients receiving standard glycemic control was significantly lower in the intensive BP treatment group than in the standard BP treatment group, whereas that in patients receiving intensive glycemic control did not differ significantly between the 2 groups. Furthermore, the risk of all-cause mortality in patients receiving intensive glycemic control was nonsignificantly higher in the intensive BP treatment group than in the standard BP group. An association between the intensive BP treatment and decreased risk of cardiovascular events in patients receiving standard glycemic control was observed in the relevant, important subgroups.
Recent systematic review and meta-analysis have suggested that the primary preventive BP lowering is associated with a reduced risk of death and cardiovascular events if the baseline systolic BP is ≥140 mm Hg and treatment at lower BP levels is not associated with any benefit in primary prevention. 7 The ACCORD BP study demonstrated that an intensive systolic BP target of <120 mm Hg did not reduce the risk of cardiovascular events, compared with the target of <140 mm Hg. 1 A current guideline recommends a systolic BP goal of 140 mm Hg and a diastolic BP goal of <90 mm Hg in patients with diabetes mellitus and hypertension. 8 The definition of composite cardiovascular events in the ACCORD BP study did not include heart failure. The number of patients with heart failure has been increasing worldwide. 9, 10 Because patients with diabetes mellitus have an increased risk of heart failure, 11 it is important to reduce the risk of heart failure, as well as that of coronary heart disease and stroke in them. The present study revealed that intensive BP treatment in patients receiving standard glycemic control reduced the risk of cardiovascular events, including heart failure compared with standard BP treatment. The results were verified by several sensitivity analyses and the effects of the intensive BP treatment were found in the clinically important subgroups. However, in patients receiving intensive glycemic control, the intensive BP treatment did not show these beneficial effects. Intensive glycemic control in the ACCORD study resulted in the increased risk of all-cause and cardiovascular mortalities. 3 Although the exact reason remains unknown, several studies have indicated that severe hypoglycemia, which occurs more frequently in patients receiving intensive glycemic control than in those receiving standard glycemic control, is associated with increased risk of mortality. 12, 13 Severe hypoglycemia leads to the activation of the sympathoadrenal system and results in significant BP elevation. 14, 15 Based on these pathophysiological mechanisms, the effects of intensive BP treatment in patients receiving intensive glycemic control might be attenuated by severe acute BP elevations because of severe hypoglycemic episodes. In addition, significant hemodynamic changes may lead to further adverse cardiovascular events and death. 16, 17 In the present study, the rate of the primary-outcome event was the highest in the standard BP treatment group in patients receiving the standard glycemic control. Meanwhile, the all-cause and cardiovascular mortality rates were the highest in the intensive BP treatment group in patients receiving the intensive glycemic control. The ACCORD study revealed that, compared with the standard glycemic control, the intensive glycemic control resulted in an increased risk of all-cause and cardiovascular mortality possibly because of severe hypoglycemia, which is associated with the sympathoadrenal system activation and severe acute BP elevation, 3, 12, 14 whereas the intensive glycemic control was associated with a decreased risk of ischemic heart disease. 6 The risk and benefit of the intensive glycemic control and possibly large BP fluctuation in the intensive BP treatment group receiving the intensive glycemic control could be attributed to the inconsistent results in the present study. 16, 17 A recent study using combined data from the ACCORD BP and other studies found that the intensive BP treatment produced a similar favorable effect and seems to decrease cardiovascular events in both patients with and without diabetes mellitus. 18 Although the results of the study may support ours, there are several concerns about different study designs, such as eligible criteria, detailed definitions of outcomes, monitoring methods, and BP measurements. In addition, another study indicated that intensive BP treatment reduced cardiovascular events in SPRINT (Systolic Blood Pressure Intervention Trial)-eligible participants of the ACCORD BP study. 19 However, it remains unknown whether the benefit was restricted to the ACCORD BP participants with additional cardiovascular risk factors. Furthermore, a previous study found that the risk of cardiovascular events (not including heart failure) was lower in the intensive BP/standard glycemic control group, compared with the standard BP/standard glycemic control group. 20 Because the prevention of heart failure has taken on increased significance in light of recent trial results, 21 it is important to evaluate the outcomes, including heart failure in patients with diabetes mellitus. Moreover, it remains unknown whether the intensive BP treatment is beneficial or harmful for preventing cardiovascular events in patients receiving intensive glycemic control. The strength of our study is that it was performed using the ACCORD BP data alone and that intensive BP treatment showed beneficial effects in the participants without additional cardiovascular risk factors. There was a significant interaction between the BP treatment strategy and the glycemic control. Because the risk of all-cause and cardiovascular mortalities were nonsignificantly higher in the intensive BP treatment in patients receiving the intensive glycemic control, we can only recommend intensive BP treatment for patients receiving the standard glycemic control.
The present study has some limitations. First, this study was a secondary analysis of data obtained in a randomized controlled trial. In addition, early events within 1 year were combined. Although several sensitivity analyses showed significant association between the intensive BP treatment and the lower risk of the primary outcome, the P value changed from 0.005 to 0.03. Therefore, our results should be confirmed by a prospective randomized controlled trial. Second, the intensive BP treatment was associated with a decreased risk of the primary composite outcome, whereas that of the secondary outcome events, except for stroke, did not differ significantly between the standard and intensive BP treatment groups. Although we added heart failure to the primary-outcome event as an important one, the risk of heart failure itself in patients receiving the intensive glycemic control was not significantly lower in the intensive BP treatment group than in the standard BP treatment group (HR, 0.69; 95% CI, 0.44-1.11; P=0.12). In consideration of the lower event rate in the intensive BP treatment group compared with the standard BP treatment group, 1 possible explanation for nonsignificant results is that the present study is underpowered when designing the re-evaluation of the ACCORD BP trial. Originally, the ACCORD trial was underpowered given that the event rate observed in the standard BP treatment group was ≈50% lower than the expected rate. 1 The ACCORD BP trial, with a planned sample size of 4200 participants, was designed to have 94% power to detect a 20% reduction in the rate of the primary outcome for participants in the intensive BP treatment group compared with those in the standard BP treatment group, assuming a 2-sided α level of 0.05, a primary-outcome rate of 4% per year in the standard BP treatment group. However, the primary-outcome event rates were 1.87% and 2.09% per year in the intensive and standard BP treatment groups, respectively. Thus, the results of the present study may also be affected by the underpower. Although conducted on large-scale data with a robust subgroup representation, the results of the present study warrant confirmation by primary investigations with statistically appropriate sample sizes. Moreover, because the ACCORD data did not offer comprehensive information about the type of stroke, whether the intensive BP treatment may result in the lower risk of either ischemic or hemorrhagic stroke remains unclear. Hence, further studies are warranted to reveal the pathophysiology of the effects of the intensive BP treatment on stroke. Third, our findings may not be applicable to other patients with diabetes mellitus. Specifically, the ACCORD BP participants were high risk patients. Therefore, it remains unclear whether the intensive BP treatment would lead to a decreased risk of cardiovascular events in patients with low risk type 2 diabetes mellitus. Further clinical trials are needed to assess whether the intensive BP treatment reduces the risk of cardiovascular events. Fourth, a recent study using the ACCORD data reported that achieving an intensive target systolic BP <120 mm Hg failed to diminish the risk of a composite end point of fatal and nonfatal cardiovascular events in high-risk patients with diabetes mellitus compared with those unable to achieve the intensive target systolic BP goal. 22 Sometimes, the target BP levels are different from the achieved BP levels, particularly in daily clinical settings. The same is equally true for glycemic control. In addition, glycemic control in patients with diabetes mellitus exerts a direct and an indirect impact on their BP. Therefore, further studies are warranted to reveal the optimal target of BP and glycohemoglobin levels.
In conclusion, the present study demonstrated that the intensive BP treatment in patients receiving standard glycemic control was significantly associated with a decreased risk of cardiovascular events including heart failure. This association between the intensive BP treatment and decreased cardiovascular events in patients receiving standard glycemic control was also observed in the clinically important subgroups. However, intensive BP treatment did not show benefits in patients receiving intensive glycemic control. Further studies are required to confirm the safety and efficacy of intensive BP treatment in high-risk patients with type 2 diabetes mellitus.
Perspectives
The Action ACCORD BP study demonstrated that intensive systolic BP treatment in patients with type 2 diabetes mellitus did not demonstrate favorable effects. The present study demonstrated that the intensive BP treatment in patients with type 2 diabetes mellitus receiving standard glycemic control was significantly associated with a decreased risk of cardiovascular events including heart failure. This association between the intensive BP treatment and decreased cardiovascular events in patients with type 2 diabetes mellitus receiving standard glycemic control was also observed in the clinically important subgroups. However, intensive BP treatment did not show benefits in patients with type 2 diabetes mellitus receiving intensive glycemic control. Benefits of intensive BP treatment were observed only in ACCORD BP participants receiving standard glycemic control, without additional risk factors. Further studies are required to confirm the safety and efficacy of intensive BP treatment in high-risk patients with type 2 diabetes mellitus. 
